Indian API and generics firms want a bigger share of the Japanese market | 22 April, 2015

CPhI-Japan was inaugurated in a grand style as all the key representatives partner associations of UBM were called on the stage for a formal ribbon cutting ceremony.

As one of the key partner of UBM, India was represented by Deputy Chief of Mission DCM), Embassy of India in Tokyo. Recognizing India as a major partner country, UBM made an exception to the normal practice wherein inaugural ceremony happens only after the address of their Japan operation head and requested Mr Amit Kumar, Deputy Chief of Mission to address the gathering.

This was one of the most important highlight of the day for Indian Pharma. About 280 registered visitors attended the Seminar. This was considered to be the best attended programme of UBM so far in CPhI anywhere in the world. This also highlights the fact that there is certainly growing interest about Indian pharma.

The two hour seminar focused on understanding the Indian pharma sector and its competence and how it can play an important role in Japanese demand of generics which is now 30% of total pharma requirements and poised to become 60% due to govt policy.

Presentations were made by Ministry of Health and Labour Welfare and PMDA which focused on Regulatory requirements and some of the changes made recently in the regulations.

Dr Gurpreet Sandhu presented a detailed account of India’s pharma strength vis-à-vis Japan’s need. Further, he mentioned about the roadmap and the areas where in collaborative efforts could be made to explore various business opportunities. The areas would be CRAMS, APIs and dosage forms. The most important compliance would be indeed conformity to standard in Japan.

DCM in his welcome remarks talked about the recent enhanced interaction between both the governments which is being seen very conducive to facilitate the growing interest among business people to explore opportunities. Pharma sector, surely being the one poised with lots of promise.